# Prime Medicine in vivo prime editing clinical trials

> Developing situation record from CLSTR: https://clstr.news/situations/prime-medicine-in-vivo-prime-editing-clinical-trials
> Updated: 2026-10-29T00:30:07.000Z. Sources: 13. Developments: 2.

Prime Medicine has initiated a Phase 1/2 clinical trial using in vivo prime editing to treat Wilson disease, a rare genetic condition caused by mutations in the ATP7B gene. This method utilizes lipid nanoparticles to deliver editing machinery directly to liver cells to correct mutations, aiming for a permanent, “one-and-done” solution rather than lifelong medication.

This approach represents a shift in gene therapy, moving from traditional methods that require modifying cells outside the body to a “search-and-replace” engine capable of rewriting DNA directly inside the human body with minimal genomic damage. While the current focus is on Wilson disease, researchers suggest this technology could eventually be applied to common conditions such as heart disease, obesity, and diabetes.

## Timeline

### 2026-10-29: Gene editing technology advances toward treating common diseases

Gene editing is expanding from rare disease treatments to common conditions like heart disease, with new prime editing trials testing in-body DNA rewriting for Wilson disease.

3 sources. https://clstr.news/cluster/gene-editing-technology-advances-toward-treating-common-diseases

### 2026-10-24: Prime Medicine treats first patient with in-body DNA prime editing

Scientists have used prime editing to correct a Wilson disease mutation directly inside a human body for the first time, potentially offering a one-time permanent cure via lipid nanoparticles.

10 sources. https://clstr.news/cluster/scientists-modify-dna-directly-inside-the-human-body

---
Cite as: Prime Medicine in vivo prime editing clinical trials. CLSTR, https://clstr.news/situations/prime-medicine-in-vivo-prime-editing-clinical-trials